PMV Pharmaceuticals, Inc. (PMVP) Stock: Price, Forecast & Analyst Target
PMV Pharmaceuticals, Inc. (PMVP) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $1.31 (+7.38%), as of the Nov 19, 2026 trading session; market cap $99.0M.
Educational signal · not a buy or sell recommendation · How to read this
PMV Pharmaceuticals, Inc. · PMVP · NASDAQ
PMV Pharmaceuticals, Inc.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · PMV Pharmaceuticals (PMVP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, weak growth and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Fading; Momentum: Rising.
Free cash flow yield is the main valuation drag relative to sector peers.
- EPS beat 0 of the last 3 reports
- Altman Z -6.99 · Piotroski F 1
- ROE -99.4% · ROA -39.3% · current ratio 9.81
Holding back: weak fundamentals, a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 31 | Weak | |
| 31 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.31 | |
| Change on the day | +7.38% | |
| 52-week range | $1.02 – $1.91 | |
| Market capitalisation | $99.0M | — |
| Shares traded on the day | 1.19M |
Price & events
Other perspectives
Council score for PMV Pharmaceuticals (PMVP): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Five of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens, Simons-style lens, Englander-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens disagrees with the Valuation pillar (Bubble, 3 of 100): it reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is PMV Pharmaceuticals (PMVP), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. PMV Pharmaceuticals, Inc. (PMVP) is listed on NASDAQ. It employs 54 people and is led by David H. Mack. The market values it at $99.0M.
What do the latest results show for PMV Pharmaceuticals (PMVP)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 3 reports.
What are the financial strengths and risks for PMV Pharmaceuticals (PMVP)?
Short answer
What is holding it back is weak fundamentals, a rich price, soft growth. The distress and quality screens read Altman Z -6.99 · Piotroski F 1. Trailing ratios: ROE -99.4% · ROA -39.3% · current ratio 9.81.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -6.99 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-99.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at PMV Pharmaceuticals (PMVP)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $2.92M · EPS -1.32 · 4 analysts. Current published price targets run low $5.00 · high $5.00 · consensus $5.00 · median $5.00 against a quoted price of $1.31 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for PMVP.
Checked against the records this page reads, on the dates shown above.
How does PMV Pharmaceuticals compare with its peers?
Short answer
PMV Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| PMV Pharmaceuticals (PMVP) — this page | $1.31 | $99.0M | 31 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $5.00 – $5.00
- Consensus target
- $5.00
- Median target
- $5.00
- Revenue estimate
- $2.92M
- EPS estimate
- $-1.32
Consensus record · Captured .
Measured against a quoted price of $1.31 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 8
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 0
- Other transactions
- 8
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PMVP in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PMVP in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about PMV Pharmaceuticals (PMVP)?
What Investors Ask About PMV Pharmaceuticals (PMVP)
These answers are editorial: 1 of these 9 answers is drawn from the PMVP research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for PMVP?
PMVP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is PMVP a good stock to buy?
Stock Expert AI does not rate PMVP buy, sell or hold. PMV Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PMVP stock price today?
The last price recorded for PMV Pharmaceuticals, Inc. (PMVP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PMVP price target?
The analyst consensus price target for PMV Pharmaceuticals, Inc. (PMVP), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for PMVP?
The main risks for PMV Pharmaceuticals, Inc. include the potential for clinical trial failures or delays, regulatory setbacks, and competition from other companies developing cancer therapies.
What are the key factors to evaluate for PMVP?
PMV Pharmaceuticals, Inc. (PMVP) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does PMVP data refresh on this page?
PMVP's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PMVP's recent stock price performance?
PMV Pharmaceuticals, Inc. (PMVP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PMVP overvalued or undervalued right now?
PMV Pharmaceuticals, Inc. (PMVP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 10 from Financial Modeling Prep (FMP), 9 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com